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Abstract: 
 
Echinacea preparations, which are used for the prevention and treatment of upper respiratory 
infections, account for 10% of the dietary supplement market in the U.S., with sales totaling 
more than $100 million annually. In an attempt to shed light on Echinacea's mechanism of 
action, we evaluated the effects of a 75% ethanolic root extract of Echinacea purpurea, prepared 
in accord with industry methods, on cytokine and chemokine production from RAW 264.7 
macrophage-like cells. We found that the extract displayed dual activities; the extract could itself 
stimulate production of the cytokine TNF-α, and also suppress production of TNF-α in response 
to stimulation with exogenous LPS. Liquid:liquid partitioning followed by normal-phase flash 
chromatography resulted in separation of the stimulatory and inhibitory activities into different 
fractions, confirming the complex nature of this extract. We also studied the role of alkylamides 
in the suppressive activity of this E. purpurea extract. Our fractionation method concentrated the 
alkylamides into a single fraction, which suppressed production of TNF-α, CCL3, and CCL5; 
however fractions that did not contain detectable alkylamides also displayed similar suppressive 
effects. Alkylamides, therefore, likely contribute to the suppressive activity of the extract but are 
not solely responsible for that activity. From the fractions without detectable alkylamides, we 
purified xanthienopyran, a compound not previously known to be a constituent of the Echinacea 
genus. Xanthienopyran suppressed production of TNF-α suggesting that it may contribute to the 
suppressive activity of the crude ethanolic extract. Finally, we show that ethanolic extracts 
prepared from E. purpurea plants grown under sterile conditions and from sterilized seeds, do 
not contain LPS and do not stimulate macrophage production of TNF-α, supporting the 
hypothesis that the macrophage-stimulating activity in E. purpurea extracts can originate from 
endophytic bacteria. Together, our findings indicate that ethanolic E. purpurea extracts contain 
multiple constituents that differentially regulate cytokine production by macrophages. 
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Abstract
Echinacea preparations, which are used for the prevention and treatment of upper respirato-
ry infections, account for 10% of the dietary supplement market in the U.S., with sales total-
ing more than $100 million annually. In an attempt to shed light on Echinacea'smechanism
of action, we evaluated the effects of a 75% ethanolic root extract of Echinacea purpurea,
prepared in accord with industry methods, on cytokine and chemokine production from
RAW 264.7 macrophage-like cells. We found that the extract displayed dual activities; the
extract could itself stimulate production of the cytokine TNF-α, and also suppress produc-
tion of TNF-α in response to stimulation with exogenous LPS. Liquid:liquid partitioning fol-
lowed by normal-phase flash chromatography resulted in separation of the stimulatory and
inhibitory activities into different fractions, confirming the complex nature of this extract. We
also studied the role of alkylamides in the suppressive activity of this E. purpurea extract.
Our fractionation method concentrated the alkylamides into a single fraction, which sup-
pressed production of TNF-α, CCL3, and CCL5; however fractions that did not contain de-
tectable alkylamides also displayed similar suppressive effects. Alkylamides, therefore,
likely contribute to the suppressive activity of the extract but are not solely responsible for
that activity. From the fractions without detectable alkylamides, we purified xanthienopyran,
a compound not previously known to be a constituent of the Echinacea genus. Xanthieno-
pyran suppressed production of TNF-α suggesting that it may contribute to the suppressive
activity of the crude ethanolic extract. Finally, we show that ethanolic extracts prepared from
E. purpurea plants grown under sterile conditions and from sterilized seeds, do not contain
LPS and do not stimulate macrophage production of TNF-α, supporting the hypothesis that
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the macrophage-stimulating activity in E. purpurea extracts can originate from endophytic
bacteria. Together, our findings indicate that ethanolic E. purpurea extracts contain multiple
constituents that differentially regulate cytokine production by macrophages.
Introduction
Echinacea is the third most popular herbal medicine in the US, with annual sales of over $100
million [1]. Preparations from several species of this botanical (most commonly E. purpurea
and E. angustifolia) are used for the treatment of upper respiratory viral infections such as
colds and flus, and there is considerable controversy over their efficacy for this purpose (re-
viewed in [2]). Several clinical trials have demonstrated positive results. For example, Jawad
et al. [3] treated subjects for 4 months and found a significant reduction in both total number
and severity of cold episodes. On the other hand, Barrett et al. [4] failed to find an effect when
Echinacea was used for several days to treat colds once symptoms had emerged. A confounding
factor in interpreting the results of clinical trials is the complexity and variability of Echinacea
products tested. Echinacea preparations used in clinical trials have been extracted from differ-
ent species, different portions of the plant (containing different constituents), and by different
processes. In the studies cited above, Jawad et al. [3] used a commercial preparation referred to
as “Echinaforce”, an ethanol extract of leaves (95%) and roots (5%) of E. purpurea, while the
study conducted by Barrett et al. [4] utilized roots from E. purpurea and E. angustifolia, that
were ground whole and dispensed in pill form. There is currently a lack of knowledge regarding
how to prepare Echinacea extracts with specific, desirable biological activities, and which con-
stituents serve as appropriate biomarkers of these activities.
In an attempt to shed light on the mechanism of action of Echinacea preparations, their
immunodulatory activity has been tested in vitro, primarily with studies focusing on macro-
phages and epithelial cells. During respiratory virus infection, activation of various host pattern
recognition receptors (PRRs) on macrophages and epithelial cells leads to the production of
pro-inflammatory cytokines, chemokines, and lipids. These molecules in turn bind receptors
on a variety of cells types, in a variety of organs and tissues, and trigger the well-known symp-
toms accompanying respiratory infections including fever, malaise, excess mucus production,
and anorexia [5, 6]. For this reason, a number of investigators have hypothesized that the pur-
ported relief provided by Echinacea extracts arises from inhibition of pro-inflammatory media-
tor production. In vitro, this hypothesis has been tested by adding Echinacea extracts to
cultures of macrophages and epithelial cells and monitoring effects on production of inflam-
matory mediators. Unfortunately, the results of these experiments have also been confusing
and contradictory. Sharma et al. [7] (who tested Echinaforce) found broad inhibition of cyto-
kine production when a number of different respiratory viruses were used to infect epithelial
cells and macrophages. Suppression of cytokine and lipid mediator production has also been
noted with alkylamides (also referred to as alkamides), which are fatty acid-like constituents of
Echinacea, following stimulation of macrophages with both respiratory viruses [8] and bacteri-
al LPS [9, 10]. However, not all Echinacea extracts suppress cytokine production in vitro. In a
study where we examined 17 E. purpurea root extracts (prepared in 75% ethanol), from plants
grown on different farms, we found that despite high alkylamide levels, only a few suppressed
production of the mediators PGE2 and TNF-α from RAW 264.7 cells stimulated with influenza
A strain PR/8/34 [8]. In fact, many extracts actually stimulated production of these mediators.
Similarly, using aqueous, organic, and detergent-based extraction procedures, Tamta et al. [11]
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and Pugh et. al. [12, 13] found stimulation of soluble mediator production from RAW 264.7
and THP-1 macrophage-like cell lines. These authors attributed this activity to bacterial-de-
rived lipopolysaccharide (LPS) and lipoproteins found in the extracts, and suggested that these
compounds originated with endophytic bacteria living in the Echinacea plants. Suppression
and/or stimulation of cellular activity by Echinacea extracts has also been shown with T cells.
Sasagawa et al. [14] used a 95% ethanol extract of E. purpurea leaves and flowers and demon-
strated inhibition of phytohemagglutinin-dependent production of IL-2 with the Jurkat human
T cell line, a finding that was subsequently linked to the inhibition of the nuclear receptor
PPARγ[15]. More recently, using an aqueous E. purpurea extract with high polysaccharide
content, Fonseca et al. [16] also reported inhibition of Jurkat T cell function at low cell densi-
ties. However, these authors also reported stimulation of cell function by this extract when Jur-
kat cells were grown at higher cell densities [16]. The reason for this discrepancy is unclear.
Our laboratories are interested in understanding the in vitro effects of Echinacea extracts
and their constituents. Can these models be used ultimately to predict activity in vivo? The use
of different extracts by different laboratories, yielding complex and confusing in vitro results,
suggested to us that we take a step backward and more carefully dissect the chemical basis for
the in vitro immunomodulatory activity of a single extract. Insights gained from such experi-
ments should then be useful to inform rational design of Echinacea-based therapies in vivo. In
these experiments, we hypothesized that complex Echinacea extracts contain complex mixtures
of molecules, both of botanical and bacterial origin, capable of differentially modulating im-
mune cell function. Our goal with these studies was to test this hypothesis by comparing the ef-
fects of an E. purpurea (L.) Moench (Asteraceae) ethanolic root extract, and its constituents
and fractions, on the production of cytokines and chemokines from the RAW 264.7 macro-
phage-like cell line. We also sought to explore the potential role of LPS from endophytic bacte-
ria in dictating the in vitro immunomodulatory activity of E. purpurea extracts. We focused
specifically on E. purpurea in these studies because this is the Echinacea species that has been
most widely used for medicinal purposes in the US [17].
Materials and Methods
Instrumentation
Flash chromatography separations were performed using an automated Isco CombiFlash RF
system over silica gel columns (Teledyne Isco, Lincoln, NE). High performance liquid chroma-
tography (HPLC) separations were accomplished using a Varian HPLC system (ProStar 210
pumps, ProStar 710 fraction collector, ProStar 335 photodiode array detector) with Galaxie
ChromatographyWorkstation software (version 1.9.3.2). An Acquity ultra-high performance
liquid chromatography (UHPLC) system (Waters Corporation, Milford, MA) coupled to a
LTQ Orbitrap XL Hybrid mass spectrometer (Thermo Fisher Scientific, Waltham, MA) was
used for all LC-MS analyses. NMR spectra were acquired with a JNM-ECS 400 MHz NMR
spectrometer (JOEL USA, Peabody, MA). Unless otherwise stated, all solvents used in chemical
analyses were purchased from Thermo Fisher Scientific (Waltham, MA).
Preparation and fractionation of a large scale E. purpurea root extract
Echinacea purpurea roots were purchased from Pacific Botanicals (Grants Pass, OR). A vouch-
er specimen (NCU 633811) was deposited at the North Carolina Herbarium. Roots were
rinsed, crudely cut, and allowed to dry at 37°C for 1 week. Dried root material was ground me-
chanically using a Wiley Mill Standard Model No. 3 (Arthur H. Thomas Co., Philadelphia PA)
to mesh size 2 mm. The ground root material (1.9 kg) was macerated for seven days in 75%
ethanol (Pharmaco-AAPER, Shelbyville, KY) at a ratio of 5:1 (mL of solvent:g of dried root
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material). The resulting extract was vacuum filtered using Whatman 24.0 cm grade 1 filter
paper, and the filtered extract was concentrated using a rotatory evaporator and subjected to
two stages of liquid-liquid partitioning (Fig 1). The first stage consisted of defatting by parti-
tioning between hexane and 10% aqueous methanol (1:1). Layers were separated and dried
using a rotatory evaporator. The dried aqueous methanol layer was then partitioned using
water:methanol:chloroform (4:1:5), resulting in two layers that were separated and again sub-
jected to rotary evaporation. The chloroform layer was fractionated with normal-phase flash
chromatography over a RediSep Rf silica gel column using a gradient of 100% hexane to 100%
chloroform to 100% methanol. The column eluent was combined into 13 pooled fractions
based on LC-UV chromatograms and the fractions were evaporated and stored dry at 4°C until
needed for bioassay or chemical analysis.
Isolation and identification of xanthienopyran
Fractions 9 and 10, prepared as described in the previous section, were combined based on sim-
ilar anti-inflammatory activity and LC-MS profile for a total yield of 747.7 mg. This combined
sample was subject to normal-phase flash chromatography using a RediSep Rf silica gel column
and a hexane:chloroform:methanol solvent system at a flow rate of 40 mL/min. The gradient
initiated at 50:50 (hexane:chloroform) and increased to 100% chloroform over 3 column vol-
umes, was held at 100% chloroform for 3 column volumes, decreased linearly to 10:90 (metha-
nol:chloroform) over 5 column volumes, then decreased linearly to 20:80 (methanol:
Fig 1. Partitioning scheme for the Echinacea purpurea extract.Dried E. purpurea roots (1.9 kg) were extracted in 75:25 ethanol:water, consistent with
standard practices in the dietary supplements industry. The ethanolic extract was evaporated by rotary evaporation and subjected to two stages of liquid:
liquid partitioning with hexane:methanol and chloroform. The resulting chloroform layer was fractioned into thirteen pooled fractions using normal phase flash
chromatography. These fractions were then profiled for chemical composition and subjected to biological assays. Marc, residue after extraction; EE, ethanol
extract; HL, hexane layer, ML, methane layer; AL, aqueous layer; CL, chloroform layer.
doi:10.1371/journal.pone.0124276.g001
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chloroform) over 10 column volumes, decreased linearly to 50:50 (methanol:chloroform) over
4 column volumes, decreased to 100% methanol over 2 column volumes and was held at 100%
methanol for 2 column volumes. Fractions were combined into 8 pooled fractions (A-H) based
on UV absorbance.
Fraction E eluted from column after 14 column volumes and yielded 392.9 mg. This fraction
was subjected to an additional stage of flash chromatography with a silica gel Gold column
using a hexane:ethyl acetate:methanol solvent system and a flow rate of 30 mL/min. The gradi-
ent began at 50:50 (hexane:ethyl acetate) and increased to 100% ethyl acetate over 2 column
volumes, continued isocratically at 100% ethyl acetate for 5 column volumes, decreased linearly
to 10:90 (methanol:ethyl acetate) over 5 column volumes, continued to decrease linearly for 10
column volumes to 20:80 (methanol:ethyl acetate), decreased to 100% methanol over 2 column
volumes, and was held at 100% methanol for 2 column volumes. The eluent was combined into
3 pooled fractions (I-III) based on UV absorbance.
Fraction I contained eluent from the first three column volumes (yield: 174.9 mg) and was
subject to further separation using HPLC with a Gemini-NX 5 μm, 250 × 21.2 mm C-18 col-
umn (Phenomenex Inc., Torrance, CA). Samples were eluted from the column using a binary
solvent system with solvent A consisting of water (Barnstead Nanopure Diamond, Thermo
Fisher) with 0.1% formic acid and solvent B consisting of acetonitrile (HPLC grade) with 0.1%
formic acid at a flow rate of 21 mL/min. The gradient began at 60:40 (A:B) and decreased line-
arly to 20:80 (A:B) over 20 min, then decreased linearly to 0:100 (A:B) over 5 min. and was
held at isocratic conditions for 5 min. The eluent was combined into three pooled fracitons (a-
c) based on UV absorbance. The second fraction (b) yielded 3.2 mg of 95% pure xanthieno-
pyran (1). NMR and high resolution LC-MS were employed to confirm the identification of
the isolated compound.
Quantitative analysis of alkylamides
Alkylamide concentraitons were determined using LC-MS. Each sample was re-suspended in
methanol to a concentration of 1 mg/mL prior to analysis, and serial dilutions of these solu-
tions were performed to achieve a concentration within the linear range of the calibration
curve. A 3 μL injection of each sample was eluted from the column (Acquity UPLC BEH C18
1.7μm, 2.1 × 50 mm, Waters Corp.) at a flow rate of 0.25 mL/min using the following binary
gradient with solvent A consisting of water (Optima LC/MS grade) with 0.1% formic acid addi-
tive and solvent B consisting of acetonitrile (Optima LC/MS grade) with 0.1% formic acid addi-
tive. The gradient initiated at an isocratic composition of 90:10 (A:B) for 1.0 min, increasing
linearly from 1.0–8.0 min. to 10:90 (A:B), followed by an isocratic hold at 10:90 (A:B) from
8.0–9.0 min, gradient returned to starting conditions of 90:10 (A:B) from 9.0–9.1 min, and was
held at this composition from 9.1–10 min. The mass spectrometer was operated in positive ion-
ization mode over a scan range of 150–1000 with the following setting: capillary voltage set at 5
V, capillary temperature set at 300°C, tube lens offset set at 35 V, spray voltage set at 3.80 kV,
sheath gas flow set at 35, and auxiliary gas flow set at 20.
Alkylamides were identified by comparing retention times andm/z values with previously
published literature values [18], as described in detail elsewhere. The selected-ion chromato-
grams for the six most abundant alkylamides were plotted, and the peak area was determined
for each. These peak areas were used to compare the alkylamide concentration within each of
the fractions. One of the abundant alkylamides in the 75% ethanol extracts, dodeca-2E,4Z-
diene-8,10-diynoic acid isobutylamide (5), was quantified by linear regression of an external
calibration curve generated using an dodeca-2E,4Z-diene-8,10-diynoic acid isobutylamide (5)
standard (Chromadex, Irvine CA) (Table 1). Concentrations for the remaining 5 alkylamides
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was estimated using the regression parameters for the dodeca-2E,4Z-diene-8,10-diynoic acid
isobutylamide calibration curve.
Quantitative analysis of lipopolysaccharides
To quantify lipopolysaccharide (LPS) levels in the extracts from sterilized E. purpurea plants, a
small amount (0.16–19.55 mg) of each was re-suspended in 1 mL of ethanol (PHARMA-
CO-AAPER, USA). Each suspension was then diluted 1:1000 with endotoxin free water, and
LPS was quantified using the Chromo-LAL assay (Associates of Cape Cod Inc., Falmouth,
MA). Reagents were provided by Associates of Cape Cod Inc. and analyses were performed on
a Synergy H4 Microplate Reader (BioTek Instruments, Inc, Winooski, VT).
Growth and extraction of Echinacea purpurea under aseptic conditions
E. purpurea seeds were obtained from Horizon Herbs, LLC (lot # 6784, Williams, OR) and a
voucher for the whole E. purpurea plants form this source is on file at the North Carolina Her-
barium (NCU583422). Two methods were used to sterilize seeds prior to germination. With
the first method, designed to remove surface bacteria but not bacterial endophytes (bacteria liv-
ing inside the seeds), the achene pericarp was removed, and the seeds were subjected to a sur-
face sterilization procedure slightly modified from that reported by Leuchtmann and Clay [19].
Sterilization was accomplished by sequential soaking for 1 min. in ethanol (70%), followed by 4
min. in sodium hypochlorite solution (~4.5%), and finally 30 sec in ethanol (70%). The seeds
were then rinsed in sterile water and germinated as described below.
A second sterilization procedure was used to kill both surface and endophytic bacteria. This
process included an added step of removal of the seed epidermis prior to sterilization. To
Table 1. Alkylamide content of an Echinacea purpurea extract, chloroform layer, and column fractions from the chloroform layer.
Sample Concentration of alkylamide 5 ± SD (μg/mg extract)a Estimated total alkylamide content ± SD (μg/mg extract)
95% ethanol extract 7.9 ± 0.57 51 ± 8.2
Chloroform layer 26 ± 1.1 140 ± 4.7
Fraction 1 - -
Fraction 2 Below LOQb Below LOQ
Fraction 3 NDc ND
Fraction 4 ND ND
Fraction 5 ND ND
Fraction 6 63 ± 12 310 ± 42
Fraction 7 ND 2.2 ± 0.38
Fraction 8 ND 0.14 ± 0.034
Fraction 9 Below LOQ Below LOQ
Fraction 10 ND ND
Fraction 11 ND ND
Fraction 12 ND ND
Fraction 13 ND ND
a. Concentration is reported for one of the major alkylamides in the extract, alkylamide 5 in Fig 3 (dodeca-2E,4Z-diene-8,10-diynoic acid isobutylamide).
The total alkylamide concentration was estimated using the calibration curve for this compound. Reported concentrations are means+/- SD from triplicate
measurements by LC-MS as described in the Materials and Methods.
b. Below LOQ (limit of quantification) indicates that alkyamides were detected but were present at concentrations below the limit of quantitation for
the method.
c. ND indicates that alkylamides were not detected, i.e. not present at levels above the limit of detection (LOD).
doi:10.1371/journal.pone.0124276.t001
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remove the epidermis, pericarp-free seeds were soaked in a water bath for 20 min. at 40°C, and
individually scrubbed on a paper towel to disrupt the unicellular epidermis layer. Epidermis
fragments were removed with forceps. These seeds were then subjected to the same sterilization
method described above for the epidermis-intact seeds.
Germination was induced on water agar Petri dishes (1.5%) with seven seeds per plate. The
seeds were monitored daily for outgrowth of bacteria or fungi, and all seeds or seedlings with
signs of such contamination were excised and removed from the agar plate. After seven days,
all remaining symptomless seedlings were planted into sterile cultivation containers (Plantcon,
MP Biomedicals, LLC, Solon, OH), which contained 150 mL agar with Murashige Skoog media
[20] adjusted to pH = 7 and were maintained in sterile conditions at 25/25°C and 12 hr day/
night cycle in a climate chamber (Adaptis A1000, Conviron, Pembina, ND) until harvest.
Individual E. purpurea plants were harvested in a laminar flow hood, and transferred to
sterile 100 mL glass bottles, lyophilized for 48 hr, and stored at -80°C until extraction. Each
plant was extracted in 8 mL of 75% ethanol. Extracts were filtered using a 0.2 μm puradisc filter
(Whatman, GE Healthcare UK Limited, UK) connected to a nonpyrogenic syringe (Henke
Sass Wolf, Germany). An aliquot (1 mL) of each extract was diluted 1:1000 with water and ana-
lyzed using the Chromo-LAL assay as previously described. An additional 1 mL aliquot of each
plant extract was evaporated to dryness in a preweighed vial to determine mass of plant materi-
al per volume of extract.
Cell culture
Ethanol was used as the vehicle for E. purpurea extracts, partitions and fractions in all cell cul-
ture experiments. The maximum ethanol concentration was 1% in all assays and was found
not to affect cytokine production. RAW 264.7 cells were obtained from the American Type
Culture Collection, USA and were cultured in Dulbecco's modification of Eagle’s medium
(DMEM) supplemented with 4 mM L-glutamine, 4.5 g/L glucose, and 3.7 g/L sodium bicar-
bonate, 10% fetal bovine serum (FBS) at 37°C with 5% CO2. Media and supplements were ob-
tained from Caisson Labs (Logan, UT) and Sigma Aldrich (St. Louis, MO). FBS was obtained
from Gemini Bio-Products (Sacramento, CA).
Cell treatment and cytokine measurements
For bioassay of crude extracts and partition layers, RAW 264.7 cells were seeded into 24-well
tissue culture plates (Genesee Scientific, USA) at a density of 1.5 x 105 cells/well and allowed to
adhere for 24 hr. Extract, partition layers, and fractions were added at indicated concentrations.
The extracts prepared from endophyte-free plants were tested by adding 6.7 μL directly to the
cell culture medium under the conditions described previously [8]. For analysis of column frac-
tions, RAW 264.7 cells were seeded into 96-well plates at 2.5 x 104 cells/well. Treatments in-
cluded each fraction or starting material alone or in combination with 10 or 100 ng/mL of LPS
from Salmonella minnesota R595 (List Biological Laboratories, USA) for 16–18 hr. Superna-
tants were collected, centrifuged at 16,000 x g for 5 min. and stored at -80°C until analysis.
TNF-α, CCL3/MIP-1α and CCL5/RANTES ELISA kits were purchased from R&D Systems,
USA or eBioscience, USA. Optical density was determined using a Synergy HT microplate
reader (BioTek Instruments, Inc.). Cytokine concentrations were interpolated from
standard curves.
Cytotoxicity assay
RAW 264.7 cells were seeded into 96-well plates and treated with each fraction or starting ma-
terial alone under the conditions described previously. Supernatants were collected after an 18
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hr. incubation and analyzed for lactate dehydrogenase (LDH) activity using a commercially
available kit according to the manufacturer’s instructions (Thermo Fisher Scientific). Briefly, in
a 96-well plate, 50 μL of supernatant was incubated with 50 μL of reaction mixture containing
a tetrazolium salt that is reduced to formazan in the presence LDH. The plate was incubated
for 30 min. protected from light before 50 μL of stop solution was added. The absorbance was
read at 490 nm with absorbance at 690 nm subtracted to remove background. Vehicle treated
cells were lysed with lysis buffer and used as the maximum LDH release.
Statistical analyses
Significant differences between means were determined using the Student’s T test with Graph-
Pad Prism software (GraphPad Software, San Diego, CA). Levels of significance are indicated
in individual figure legends.
Results and Discussion
The broad objective of these studies was to develop a more complete understanding of the ac-
tivity of an E. purpurea extract, and its constituents, on the production of cytokines and che-
mokines by macrophages. To achieve this goal, we utilized the RAW 246.7 murine
macrophage-like cell line as a model, rather than primary mouse macrophages. With the use of
this cell line, it was possible assay the large number of samples produced as a result of these ex-
periments. RAW 264.7 cells have been used extensively in studies of macrophage cytokine pro-
duction, and, like primary murine or human macrophages, produce an array of inflammatory
cytokines and chemokines following stimulation with agonists such as LPS. We have shown
that these cells produce high levels of six cytokines and chemokines following LPS stimulation,
including TNF-α, IL-6, G-CSF, CCL2 (MCP-1), CCL3 (MIP1-α), and CCL5 (RANTES) [21].
In the experiments described in this manuscript, we focused largely on RAW 264.7 cell produc-
tion of TNF-α. TNF-αas was selected because it is a key inflammatory cytokine whose overpro-
duction has been linked to several chronic and acute inflammatory disorders such as
inflammatory bowel disease [22], psoriasis [23], and rheumatoid arthritis [24]. We and others
have shown that Echinacea extracts are capable of modifying TNF-α production [7, 21] and a
more complete understanding of these effects may lead to useful treatments for disease. In our
experiments, we also sought to obtain a broader view of the impact of E. purpurea extracts on
RAW 264.7 cell secretory activity, and therefore we expanded our analysis to include two of the
chemokines mentioned above (CCL3 and CCL5). Finally, we tested each E. purpurea extract or
fraction using two complementary approaches. The ability of the samples to induce the pro-
duction of inflammatory cytokine and chemokines production was evaluated by adding them
directly to RAW 264.7 cells in media with appropriate solvent controls. Alternatively, the in-
hibitory activity of the samples on production of inflammatory cytokines and chemokines was
tested by adding them to RAW 264.7 cells that had been activated by the addition of LPS.
Extract preparation and influence on cytokine secretion
Our studies employed an E. purpurea extract that was prepared consistent with practices com-
monly employed in the dietary supplements industry. E. purpurea roots were collected, dried,
and extracted in 75% ethanol. The ethanol extract (EE) was then tested in vitro for its effects on
production of TNF-α from RAW 264.7 cells. This extract reproducibly induced the production
of TNF-α (Fig 2), with 10 ng/mL typically accumulating in cultures with a 24 hr treatment.
This amount was similar when concentrations of both 50 and 100 μg/mL of the extract were
tested (Fig 2A and 2B), suggesting that the maximum level of stimulation had been reached.
From a comparative perspective, the level of TNF-αinduced by the extract was not very high
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for these cells under these culture conditions. For example, as shown in Fig 2C and 2D, levels
of TNF-α can exceed 30 ng/mL when a dose of 100 ng/mL is used to stimulate RAW
264.7 cells.
The ethanolic extract (EE) was also tested for its ability to inhibit production of TNF-α in
the presence of LPS (Fig 2C and 2D). At a concentration of 50 μg/mL, it displayed a significant
but weak suppressive activity of approximately 10–20% (Fig 2C). However, at the higher,
100 μg/mL concentration, the suppressive effect was much more pronounced, approaching
50% (EE, Fig 2D). Apparently, the molecules mediating the suppressive effect were not present
at sufficient concentration when the extract was tested at 50 μg/mL, and the higher 100 μg/mL
concentration was necessary to observe the suppressive effect. It is likely that this activity
would have been overlooked had we not tested higher extract concentrations. We concluded,
therefore, that the complex ethanolic E. purpurea extract contains molecules capable of both
stimulating and inhibiting macrophage secretion of TNF-α and that it is critical to examine a
range of extract concentrations to detect these activities in vitro. It is also clear that the net ef-
fects of this extract to either stimulate or suppress production of TNF-α should be thought of
as the sum of multiple, possibly opposing activities rather than as a single stimulatory or sup-
pressive activity. In the future, it will be interesting to determine whether both activities are
bioavailable in vivo and whether they offset each other’s effectiveness.
Fig 2. Influence of 75% ethanol extract and liquid:liquid partitions from Echinacea purpurea extract on TNF-α production by RAW 264.7 cells.
Extract and partitions were tested at concentrations of 50 μg/mL (A and C) and 100 μg/mL (B and D) expressed as mass of extract per assay well volume.
Cells were unstimulated in A and B and stimulated with 100 ng/mL LPS in C and D. Supernatants were harvested after 16–18 hr. and levels of TNF-α
measured by ELISA. M, media; L, LPS; EE, ethanol extract; HL, hexane layer, ML, methane layer; WL, water layer; CL, chloroform layer. Values shown are
means +/- SD from a single representative experiment. Statistical analysis was performed using the Student’s T test, *p<0.05, **p<0.01, ***p<0.001.
doi:10.1371/journal.pone.0124276.g002
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Fractionation and alkylamide content of the extract
Alkylamides from E. purpurea are well known to suppress production of inflammatory media-
tors in vitro [8, 9, 25], and are used as markers for standardization of some E. purpurea prepa-
rations. Thus, we sought to determine if the ability of the complex ethanolic E. purpurea
extract to suppress secretion of TNF-α could be attributed to the presence of alkylamides.
Quantitative analysis of the alkylamide content of the ethanolic E. purpurea extract indicated
that it contained approximately 51 μg/mg (5.1%) total alkylamides, which corresponds to an
assay concentration of 2.6 μg/mL alkylamides in Fig 2C. Previously, a higher concentration of
alkylamides has been reported to be necessary to significantly suppress TNF-α secretion by
RAW 264.7 cells (6–12 μg/mL) [8]. Thus, we suspected that components besides alkylamides
contributed to the activity of the crude E. purpurea extract. To investigate this further, the ex-
tract was partially purified with two stages of liquid-liquid partitioning (Fig 1), and each of the
resulting layers was tested for its ability to induce or inhibit the production of TNF-αby RAW
264.7 cells. As shown in Fig 2A and 2B, the stimulatory activity was generally conserved in the
methanol and chloroform layers (ML and CL, respectively). The chloroform layer also demon-
strated significant suppressive activity, as did the hexane layer (HL) (Fig 2C and 2D).
An additional level of fractionation, using flash chromatography over silica gel (Fig 1), was
undertaken to further purify the components responsible for the cytokine-suppressive activity
of the E. purpurea extract. The chloroform layer was chosen as starting material for these frac-
tionation efforts, but it is notable that additional anti-inflammatory constituents could be pres-
ent in the hexane layer (HL), which will be the focus of future studies. The chloroform layer
was separated into thirteen fractions, and the original chloroform layer and each fraction was
analyzed for alkylamide content. E. purpurea can produce an array of alkylamides that differ in
chain length and number and placement of double and triple bonds in the fatty acid portion of
the molecule [26]. Analysis of the chloroform layer indicated the presence of a number of
structurally distinct alkylamides (Fig 3). Consistent with previous reports [8], alkylamide 11a/b
was the dominant alkylamide. The alkylamide numbering system used here has been published
previously [18], and can be cross-referenced with that used by Bauer [26].
As a result of the partitioning process, the alkylamide content of the chloroform layer was
increased 2.7-fold as compared to that of the ethanol extract, for a total alkylamide content of
140 ± 4.7 μg/mg (Table 1). Similarly, fractionation of the chloroform layer concentrated the
alkylamides into fraction 6, which contained 310 ± 42 μg/mL alkylamides (Table 1), a 2.2-fold
increase. Thus, the chloroform layer and fraction 6 contained alkylamides within the concen-
tration range previously demonstrated to be biologically active [8], assay concentrations of
7.0 μg/mL and 15.5 μg/mL total alkylamides, respectively, for the experiment reported in Fig
2C.
Testing with RAW 264.7 cells revealed that three of the fractions (2, 3 and 13) strongly stim-
ulated the production of TNF-α (Fig 4A). In contrast, production of TNF-α was significantly
inhibited by fractions 6–10 (Fig 4B). These results further substantiate the presence of both
stimulatory and inhibitory activities present in the original E. purpurea extract, and indicate
that chemical manipulations can be used to separate these activities from each other. It may be
possible, therefore, to use standard chemical processes to produce extracts with, for example,
enhanced suppressive activity.
Consistent with our earlier prediction, the results in Fig 4B indicate that the alkylamides are
not solely responsible for the suppressive effects noted in the chloroform layer. As expected,
the alkylamide-rich fraction 6 did suppress the LPS-induced production of TNF-α but several
other fractions (7–10) exerted this effect as well. The suppressive effects of these fractions must
be explained by the presence of other compounds. Other bioactive small molecules previously
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reported as constituents of E. purpurea, such as the phenolic compounds caftaric acid and
cichoric acid [27], and various ketone derivatives [10], could play a role in this activity. Overall,
however, we suspect that the TNF-α suppressive activity of E. purpurea extracts is due to the
collective action of a host of small molecules, many of which have not yet been identified.
Fig 3. Alkylamides from Echinacea purpurea. Chromatogram (A) of the crude chloroform layer (CL) from the E. purpurea extract showing the presence of
a series of alkylamides (3,4,5,8,9,10,11A,11B,14,15) which were identified according to molecular weight and retention time. The relative amounts of these
alkylamides in the silica gel column pooled fractions (1–13) are indicated by the peak areas shown in panel B. The numbering system used for these
alkylamides is consistent with that used in a previous report [18]. * indicates compounds detected, but not identified. The structures for seven alkylamides
selected to represent the alkylamide content are shown in panel C.
doi:10.1371/journal.pone.0124276.g003
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Cytotoxicity
In the experiments presented herein (Figs 2 and 4), we noted suppression of TNF-α produc-
tion, which could occur if the added samples cause cell death. Each sample was therefore tested
for lactate dehydrogenase (LDH), a cytosolic enzyme released from dying cells into the culture
supernatant. As shown in Fig 5, the chloroform layer and most column fractions did not dis-
play any cytotoxic effects. A low level of cytotoxicity was noted for fractions 6–9, 1–5% at
50 μg/mL and 10–25% at 100 μg/mL, respectively. Although cell toxicity may contribute some-
what to the observed activity of these fractions, it is highly unlikely that they account for the
observed 50–90% inhibition of TNF-α (Fig 4).
Identification of xanthienopyran
In an attempt to identify other compounds that play a role in the anti-inflammatory activity of
E. purpurea, the column fractions that significantly suppressed production of TNF-α from
LPS-stimulated cells but did not contain high alkylamide content (7–10) were subjected to fur-
ther purification. Several of these fractions (7 and 8) were found to be very complex and/or of
very low yield, and efforts to isolate pure compounds from them were unsuccessful. However,
the compound xanthienopyran (1) (Fig 6A) was isolated from combined fractions 9 and 10.
Xanthienopyran has previously been reported as a constituent of the fruit and seeds of various
Xanthium species [28], but this is the first report of this compound from E. purpurea. NMR
Fig 4. The effects of Echinacea purpurea extract fractions on production of TNF-α. Fractions from the flash chromatography separation of the E.
purpurea extract chloroform layer (CL) were tested for their effects on the production of TNF-α from RAW 264.7 cells in the absence (A) or presence (B) of
10 ng/mL LPS. Treatments were for 16–18 h and levels of TNF-α in supernatants were quantified by ELISA. Each fraction was tested at 50 and 100 μg/mL.
All data shown are means +/- SEM from three independent experiments. Statistical analysis was performed using the Student’s T test, *p<0.05, **p<0.01.
M, media; L, LPS; CL, chloroform layer.
doi:10.1371/journal.pone.0124276.g004
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data for xanthienopyran (S1 Fig) were in agreement with those previously published [29]. Ad-
ditionally, the measured monoisotopic mass ([M+H]+ = 317.0838) was within 2.9 ppm mass
error of the calculated mass ([M+H]+ = 317.0847).
Xanthienopyran has been shown to inhibit the production of superoxide anions in human
neutrophils [28], but its influence on macrophages has not previously been evaluated. We
found that xanthienopyran itself did not stimulate production of TNF-α (Fig 6B). However, it
caused a dose dependent inhibition of the LPS-induced production of TNF-α (Fig 6C). From
Fig 5. Cytotoxicity of Echinacea purpurea extract fractions and chloroform layer. Fractions from the
silica gel column and the chloroform layer were tested for cytotoxicity towards RAW 264.7 cells. Treatments
were for 24 h and cytotoxicity was determined using the LDH release assay. Each fraction was tested at 50
and 100 μg/mL. Data shown are means +/- SEM from three independent experiments. Statistical analysis
was performed using the Student’s T test, *p<0.05, **p<0.01, ***p<.001. M, media; CL, chloroform layer;
Ly, lysis buffer.
doi:10.1371/journal.pone.0124276.g005
Fig 6. Structure and activity of xanthienopyran. The structure of xanthienopyran was elucidated by comparison of NMR and MS data with published
values (A). The influence of xanthienopyran on TNF-α secretion by RAW 264.7 macrophage-like cells alone (B) or in the presence of 10 ng/mL of LPS (C)
was evaluated. The influence of dodeca-2E,4E-dienoic acid isobutylamide (15) on TNF-α secretion by RAW 264.7 macrophage-like cells in the presence of
10 ng/mL of LPS (C) was evaluated as comparison. Treatments were for 16–18 hr. and levels of TNF-α in supernatants were quantified by ELISA. Data
shown are means +/- SEM from three independent experiments. Statistical analysis was performed using the Student’s T test, *p<0.05.
doi:10.1371/journal.pone.0124276.g006
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these data, an IC50 of 3.4 μg/mL was calculated, very similar to the IC50 of 1.7 μg/mL reported
for inhibition of superoxide production from neutrophils [28]. Taken together, our data sug-
gest that alkylamides and xanthienopyran contribute to, but do not entirely explain, the activity
of the E. purpurea extract to suppress the LPS-induced production of TNF-α.
The broad nature of the suppressive effect
The experiments described thus far have focused on TNF-α as an indicator of macrophage me-
diator production. However, this cytokine is only one of several cytokines and chemokines pro-
duced by RAW 264.7 cells following treatment with LPS or other pathogen associated
molecular patterns. Previously, we [8] and others [7, 9] have performed comprehensive studies
of Echinacea extracts and their effects on macrophage secretory products, and this was not our
goal in this investigation. It was of interest, however, to evaluate whether the activities we were
monitoring were specific for TNF-α or also extended to other cytokines or chemokines. To this
end, we quantified levels of CCL3 and CCL5, chemokines known to play important roles in a
variety of inflammatory processes [30, 31], in RAW 264.7 cell supernatants. As with TNF-α,
fractions 2, 3, and 13 strongly induced production of CCL3 (Fig 7A). Lesser but significant
amounts were induced by the original chloroform layer, similar to the effects noted of this
layer on production of TNF-α. For CCL5, as shown in Fig 7B, significant increases were again
induced by fractions 2, 3, and 13, although it is notable that levels of this chemokine were rela-
tively low. The chloroform layer did not induce a significant increase in the level of CCL5.
Fig 7. Echinacea purpurea fraction effects on CCL3 and CCL5. Fractions from the silica gel column were tested for their effects on the production of
CCL3 (MIP1-α) and CCL5 (RANTES) from RAW 264.7 cells in the absence (A and B) or presence (C and D) of 10 ng/mL LPS. Treatments were for 16–18 hr.
and chemokine levels in supernatants were quantified by ELISA. Each fraction was tested at 50 μg/mL. Data shown are means +/- SEM or SD from three
(CCL3) and two (RANTES) independent experiments. Statistical analysis was performed using the Student’s T test, *p<0.05. M, media; CL, chloroform layer.
doi:10.1371/journal.pone.0124276.g007
Cytokine-Inducing and Cytokine-Suppressive Constituents of E. purpurea
PLOSONE | DOI:10.1371/journal.pone.0124276 May 1, 2015 14 / 20
CCL3 and CCL5 were also quantified in supernatants from RAW 264.7 cells stimulated
with LPS. As shown in Fig 7C, suppression of CCL3 was generally found for the same samples
responsible for suppression of TNF-α (samples 6–10 and CL), although in these assays the sup-
pression by fractions 8 and 10 did not reach a statistical level of significance. Similarly, the
same set of samples generally inhibited production of CCL5, with fractions 7 and 8 and the
chloroform layer displaying significant inhibition. Interestingly, we also noted that fractions 2
and 3 strongly inhibited production of CCL5, suggesting that additional suppressive com-
pounds exist in these fractions whose activity only becomes “visible” when the level of stimula-
tion is low. Overall, our experiments suggest that the stimulatory and inhibitory effects of the
chloroform layer and fractions are not specific for production of TNF-α and likely represent
more general effects on the secretory products of RAW 264.7 cells. On the other hand, the
CCL5 assays further highlight the complexity of the extract and even the fractions collected
from the silica gel column. Dominant stimulatory or inhibitory compounds may be masking
opposing activities and the activity of these opposing compounds will not be revealed until the
dominant compounds are removed or the activities can be separated.
The role of bacterial endophytes in stimulatory activity of E. purpurea
Tamta et al. [11] and Pugh et. al. [13] have previously shown that macrophage stimulatory ac-
tivity of E. purpurea extracts can arise from LPS and lipoproteins of bacterial origin. Based on
these reports, we employed the Chromo-LAL assay to measure the quantity of bacterial LPS in
the original ethanolic E. purpurea extract. The extract was found to contain LPS at a concentra-
tion of 14.6 ± 8.4 EU/mg (where 14.6 represents the mean of two independent experiments,
each performed in triplicate (N = 6) and 8.4 is the standard deviation associated with these
measurements). As indicated by the poor precision of these measurements, quantification of
LPS levels in the ethanol extract proved difficult. Excessive well to well variation was observed
in the Chrom-LAL assay of the extract (but not LPS standards), and levels of LPS in the extract
were observed to decrease over time with repeated assays. The high well to well variability
could be explained by the inhomogeneous nature of the dried ethanol extract, which had a tar-
like consistency, making it very difficult to solubilize (even with extensive sonication). There is
literature precedent that endotoxin can exist in aggregates, and that the nature of these aggre-
gates dictates biological activity [32]. It is likely that LPS aggregates in the poorly solubilized ex-
tract are unevenly distributed among assay wells, giving rise to assay variability.
Although precise measurements of LPS levels in the ethanolic E. purpurea extract were diffi-
cult, our experiments did indicate the presence of bacterial LPS in this extract. Taking these ex-
periments a step further, it was of interest to test the hypothesis that this LPS could result from
bacterial endophytes (bacteria that live in the plant without causing overt disease). This hy-
pothesis has previously been proposed by Pasco [12, 13], and was shown to hold for studies
with alfalfa plants, but not tested for Echinacea plants. To evaluate the role of bacterial endo-
phytes in immunostimulatory activity of E. purpurea, E. purpurea plants were grown in a sterile
environment from sterilized seeds. At approximately 6 weeks of age, the plants were harvested
and extracted with 75% ethanol under aseptic conditions. The plants were small, so we used
the entire plant and not just the roots to produce the ethanol extract. The extracts were then
tested for LPS levels, and for their ability to stimulate production of TNF-αfrom RAW 264.7
cells. As a negative control to account for LPS introduced though laboratory manipulation, an
extract was prepared from an empty vessel to which no plant material was added. As a positive
control, this experiment included a plant grown under identical conditions to the sterile plants,
but from a seed that had been subjected to surface sterilization only (a process that removes
surface bacteria, but preserves endophytes). This positive control plant was selected from
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among 44 individual E. purpurea plants cultivated from surface sterilized seeds, and was inten-
tionally chosen because extraction of this plant produced moderately high levels of LPS (plant
49, S1 Table).
The extracts prepared from sterile seeds, and the negative control, contained very low LPS
levels (on the order of the limit of detection, Fig 8). The low levels of LPS observed for the ster-
ilized seeds is supportive of the success of the method employed for sterilization; recent reports
from Pasco et. al. have shown a very strong correlation between levels of bacterial LPS and
plant bacterial load [13]. Conversely, LPS was readily detected in the positive control plant. As
Fig 8. Echinacea purpurea plants grown from sterilized seeds. E. purpurea seeds were sterilized
following removal of the epidermis and grown under sterile conditions for six weeks. The negative control was
prepared using the same reaction vessels and solvents as for the individual plants, but without plant material.
The seed used to grow plant 49 was subjected to surface sterilization but with epidermis intact (see S1
Table). Plants were harvested and extracts tested for LPS content (A) and ability to induce production of TNF-
α from RAW 264.7 cells after 16–18 h incubation (B). Data show the means ± SD of duplicate experiments
measuring TNF-α secretion in panel A, and the mean ± SEM of triplicate measurements of LPS content in
panel B. Statistical analysis was performed using the Student’s T test, ***p < 0.001.
doi:10.1371/journal.pone.0124276.g008
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expected, none of the samples stimulated production of TNF-α from RAW 264.7 cells except
the extract prepared from the positive control plant. These data suggest that LPS, originating
from endophytic bacteria, can indeed contribute to the stimulatory activity of E. purpurea ex-
tracts. Undoubtedly, as suggested previously [11], additional bacterial components such as
Braun type lipoproteins are also involved. Interestingly, earlier studies attributed immunosti-
mulatory activity of E. purpurea extracts to the presence of polysaccharides [33–35] produced
by the E. purpurea plant. Plant polysaccharides do not appear to be responsible for the stimula-
tory activity observed in these experiments, given that activity was lost upon seed sterilization.
Notably, however, previous studies have shown that polysaccharides are present in some aque-
ous Echinacea extracts, but not in ethanolic extracts such as those evaluated here [36]. The pos-
sible role of plant polysaccharides as compared to bacterial components in the activity of
aqueous E. purpurea extracts remains to be evaluated.
Conclusions
These studies demonstrate the complexity of the modulatory effects of E. purpurea extracts
and their constituents on cytokine production by macrophage-like cells. It is clear that ethano-
lic extracts contain multiple constituents [including alkylamides, xanthienopyran, and others)
that can suppress the production of pro-inflammatory cytokines. However, these activities can
be partially or completely masked by stimulatory compounds, including [but likely not limited
to) bacterial LPS. Our studies support the hypothesis that the macrophage-stimulatory activity
present in E. purpurea extracts can originate from bacterial endophytes. It is worth noting,
however, that in the commercial preparation of Echinacea extracts, bacteria (and their associat-
ed macrophage-stimulatory compounds) could also come from other sources, such as surface
contamination of botanical samples. Finally, our results also demonstrate that, contrary to pop-
ular belief in the dietary supplements industry, the use of ethanol as a solvent does not prevent
the extraction of LPS and other potentially immunostimulatory compounds from bacteria.
Our findings are highly relevant to the design of effective experiments with botanical medi-
cines in the laboratory and clinic. In vitro, even with a single extract and single cell type, our ex-
periments clearly demonstrate that the activity of the complex botanical preparation cannot be
predicted on the basis of a few marker compounds. Many more experiments will be required to
fully understand the activity of this extract and its constituents towards macrophages. In vivo,
the situation is undoubtedly more complex, with additional factors such as bioavailability, mul-
tiple responding cell types, and differences in host genetics influencing the effectiveness of a
complex botanical preparation. It is not surprising that the clinical trials performed with Echi-
nacea, using different preparations, different protocols, and with different often superficial
endpoint analyses, have yielded conflicting information.
Supporting Information
S1 Fig. 1H (above) and 13C NMR (below) spectra of xanthienopyran (1) [400 MHz for 1H
and 100 MHz for 13C; MeOD].
(TIF)
S1 Table. LPS levels in a series of 45 E. purpurea plants grown in a sterile environment for
three months from surface-sterilized seeds. A recent publication from the Pasco group indi-
cates that LPS content in E. purpurea extracts is strongly correlated with bacterial load of the
plant (as measured by PCR) [13]. Thus, the presence of LPS in a portion of the extracts can
likely be attributed to the presence of bacterial endophytes. Plant # 49 was selected as the
Cytokine-Inducing and Cytokine-Suppressive Constituents of E. purpurea
PLOSONE | DOI:10.1371/journal.pone.0124276 May 1, 2015 17 / 20
positive control for the experiments reported in Fig 8 because of its moderately high
LPS content.
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